Leif A. Eriksson
Papers
2
Total Citations
5
H-Index
2
About
Leif A. Eriksson is a computational and medicinal chemist whose research focuses on enzyme mechanisms, drug discovery, and the development of novel therapeutic strategies against infectious diseases. His major contributions include pioneering the use of yeast-based screening platforms to identify inhibitors of critical viral and parasitic enzymes. Notably, he led work on an automated positive selection screen in yeast that identified boron-containing compounds as inhibitors of the SARS-CoV-2 main protease (MPro), a key target for COVID-19 antiviral drugs. He also developed an experimental target-based platform in yeast for screening inhibitors of *Plasmodium vivax* deoxyhypusine synthase (DHS), an essential enzyme for parasite survival. These innovative approaches enable rapid, cell-based identification of potential therapeutics, bridging computational predictions with experimental validation. His recent publications (2024) have already garnered citations, reflecting growing interest in his yeast-based drug discovery platforms. Eriksson’s work is notable for its translational potential, offering new avenues for combating both viral pandemics and neglected tropical diseases. His research exemplifies the power of combining computational chemistry with creative biological assays to accelerate the drug development pipeline.
Research Focus
Key Achievements
Top Papers
- 1
- 2